Insider Selling: USANA Health Sciences, Inc. (NYSE:USNA) Director Sells 675 Shares of Stock

USANA Health Sciences, Inc. (NYSE:USNA) Director Gilbert A. Fuller sold 675 shares of the firm’s stock in a transaction on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Gilbert A. Fuller also recently made the following trade(s):

• On Wednesday, August 7th, Gilbert A. Fuller sold 674 shares of USANA Health Sciences stock. The stock was sold at an average price of $39.69, for a total value of $26,751.06.

USANA Health Sciences Trading Up 2.9 %

Shares of NYSE:USNA traded up $1.11 during trading on Tuesday, reaching $39.02. 52,053 shares of the company traded hands, compared to its average volume of 80,753. The firm has a market capitalization of $743.33 million, a price-to-earnings ratio of 13.40, a P/E/G ratio of 1.27 and a beta of 0.89. USANA Health Sciences, Inc. has a 52-week low of $34.15 and a 52-week high of $54.81. The business’s fifty day moving average is $37.56 and its 200-day moving average is $42.12.

USANA Health Sciences (NYSE:USNA) last announced its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.49 by $0.07. The firm had revenue of $200.22 million for the quarter, compared to the consensus estimate of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. During the same quarter last year, the firm posted $0.59 EPS. On average, sell-side analysts predict that USANA Health Sciences, Inc. will post 2.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several research analysts have recently issued reports on USNA shares. StockNews.com downgraded USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, July 24th. DA Davidson dropped their price objective on USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 23rd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BOKF NA increased its holdings in shares of USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock valued at $133,000 after purchasing an additional 2,031 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of USANA Health Sciences by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock valued at $284,000 after acquiring an additional 494 shares during the last quarter. SG Americas Securities LLC acquired a new position in shares of USANA Health Sciences in the 2nd quarter worth approximately $340,000. Exchange Traded Concepts LLC increased its holdings in USANA Health Sciences by 4.4% in the 3rd quarter. Exchange Traded Concepts LLC now owns 7,709 shares of the company’s stock valued at $292,000 after purchasing an additional 322 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System boosted its holdings in USANA Health Sciences by 22.7% in the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after purchasing an additional 1,560 shares in the last quarter. Hedge funds and other institutional investors own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.